Oxaprozin: a once-daily treatment regimen in rheumatoid arthritis

Reynolds, W.J.; Shaar, S.F.; Buik, A.; Lancee, W.J.

Journal of Rheumatology 6(3): 345-350

1979


ISSN/ISBN: 0315-162X
PMID: 385873
Document Number: 4409
The development of oxaprozin provided an opportunity to evaluate the control of inflammation in rheumatoid arthritis by a drug that can be administered once daily. A double-blind 12-week evaluation suggested comparable efficacy between 1,200 mg oxaprozin given as a single daily dose and 3,900 mg ASA given in 4 equally divided doses. A lower incidence of side effects was noted in the oxaprozin group. An open 6-month study substantiated the efficacy and safety of oxaprozin.

Document emailed within 1 workday
Secure & encrypted payments

Oxaprozin: a once-daily treatment regimen in rheumatoid arthritis